english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Imiquimod 3.75% cream (Zyclara°) in actinic keratosis

In Focus An imiquimod 3.75% cream came onto the French market in 2021, under the brand name Zyclara°. It has a lower dose strength than Aldara° (3.75% instead of 5%), and it is applied daily for two 14-day periods. What do Prescrire's editors make of this new product?
1 September 2022

How long should one wait after stopping a drug before starting a pregnancy?

Some key principles to help answer this question without relying solely on the summary of product characteristics.
1 September 2022

Prescrire's annual review of drug packaging: choose high-quality packaging for safer health care

A drug's packaging contributes greatly to the quality of care patients receive, to patients' safety, and to the safety of those around them. There were a few signs of progress in 2021, but packaging is still too often neglected by drug companies and regulators.
1 September 2022

The European Implementing Regulation on Pharmacovigilance Activities

The proposed revision is a step towards greater independence from drug companies and better control of the quality and disclosure of data, but additional improvements are needed.
1 September 2022

EMA's response to Prescrire's analysis of EMA's transparency policy over the last 10 years

The reply by the European Medicines Agency's Executive Director, in response to Prescrire's critique of the Agency's transparency policy, with comments added by Prescrire, appears in the September 2022 issue of Prescrire International.
1 September 2022

Rivaroxaban (Xarelto°) for venous thromboembolism in children and adolescents

FEATURED REVIEW Rivaroxaban is the first oral factor Xa inhibitor to be granted marketing authorisation in the European Union for use in children and adolescents. In this situation, what benefit does rivaroxaban bring, compared to a heparin derivative or warfarin? What is its adverse effect profile in children and adolescents?
Full review (3 pages) available for download by subscribers.
1 July 2022

Prescrire's analysis of EMA's transparency policy over the last 10 years: EMA's reply with Prescrire's comments

1 July 2022

In the July-August issue of Prescrire International: Indacaterol + glycopyrronium + mometasone (Enerzair Breezhaler°) in asthma

FREE DOWNLOAD How do Prescrire's editors rate this new fixed-dose combination? And what about the questions raised by a "connected drug" such as the Enerzair Breezhaler°, with its electronic sensor that can record and transmit various data?
Full text available for free download.
1 July 2022

Covid-19: delays in other types of health care

 Editorial  Over 5 million deaths have been directly attributed to the covid-19 pandemic in 2020 and 2021. The estimated number of deaths doubles to quadruples when unrecorded cases and indirect deaths due to the impact of the pandemic on other healthcare services are taken into account.
1 July 2022

Delays in access to EMA documents: the Agency confers with Prescrire

A video conference was held between the European Medicines Agency (EMA) and Prescrire to discuss the delays in dealing with Prescrire's requests for access to documents.
1 July 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90